Amoroso Michael 4

What Happened Michael Amoroso, President & CEO and a director of Precision BioSciences (DTIL), was granted 573,888 restricted stock units (RSUs) on 2026-06-01. The Form 4 lists the award as a derivative acquisition at $0.00 per unit (no cash paid on grant). This is a grant of compensation/retention equity rather than a market purchase or sale.

Key Details

• Transaction date and filing: Grant dated 2026-06-01; Form 4 filed 2026-06-03 (filed within the two-business-day Section 16 deadline).
• Amount and price: 573,888 RSUs; reported price $0.00 (award/derivative, transaction code A).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — each RSU is a contingent right to one share of common stock. F2 — award vests in three substantially equal annual installments beginning February 18, 2027, subject to continued service.

Context RSUs are a form of equity compensation that convert into shares only upon vesting; they are not immediately tradable and do not indicate an outright purchase. Grants like this are typically compensation or retention-related and should be interpreted as part of the CEO’s pay package rather than a direct market signal.